Castle Biosciences, Inc. — FY2020 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2020; quarterly figures below highlight Q4. Castle Biosciences is a commercial-stage diagnostics company focused on genomic tests for dermatologic cancers. Its products included DecisionDx-Melanoma and DecisionDx-UM, as well as the 2020 launches DecisionDx-SCC and DecisionDx DiffDx-Melanoma.
Financial performance
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $62.6 million | $51.9 million |
| Gross profit / margin | $53.0 million / 84.5% | $44.6 million / 85.9% |
| Operating income (loss) | $(6.5) million | $7.3 million |
| Net income (loss) | $(10.3) million | $5.3 million |
| Operating cash flow | $9.9 million | $7.0 million |
| Cash and cash equivalents at year-end | $409.9 million | $98.8 million |
| Long-term debt at year-end | $0 | $25.1 million |
Revenue rose 20.8%, primarily from higher per-test revenue and increased DecisionDx-Melanoma volume. Costs grew faster: R&D increased 79.5% and selling, general and administrative expense increased 61.3%. Stock-based compensation was $8.3 million, up from $1.2 million.
Q4 revenue was $17.3 million versus $17.6 million in Q4 2019; gross profit was $14.6 million versus $15.6 million. Q4 2020 net loss was $4.9 million, compared with net income of $2.1 million in Q4 2019. The 2019 quarter included a $5.2 million debt-extinguishment gain.
Operating cash flow was positive despite the annual net loss, supported in part by noncash expenses and receipt of an $8.3 million Medicare advance payment. Investing cash flow was $(4.7) million, mainly property and equipment purchases. Financing cash flow was $305.9 million, principally net proceeds from two 2020 stock offerings. The company repaid its term loan in December; the payoff totaled $21.6 million and generated a $1.4 million extinguishment loss.
Year-end liabilities included $8.4 million of Medicare advance-payment obligations, of which $6.6 million was current, and approximately $6.8 million of future minimum operating lease payments. The Medicare advance is repayable through offsets to Medicare payments beginning in April 2021, with any residual due after the recoupment period.
Material changes and operating developments
- Total test reports increased to 18,185 from 17,055. DecisionDx-Melanoma reports grew 4.5%, substantially slower than 29.1% growth in 2019; DecisionDx-UM reports fell 8.6%. The two new tests generated 485 SCC and 73 DiffDx-Melanoma reports after launch.
- Management linked weaker test-volume growth to COVID-19-related delays and cancellations of patient visits and biopsies. DecisionDx-Melanoma volume fell 18.5% year over year in Q2; management cited third-party data indicating 2020 melanoma diagnoses were down more than 20% from 2019.
- Medicare represented 58% of revenue, Medicare Advantage 29%, and BlueCross BlueShield plans 6%. Expanded Medicare coverage for DecisionDx-Melanoma took effect in late 2020. Medicare reimbursement rates disclosed for 2021 were $7,193 for DecisionDx-Melanoma and $7,776 for DecisionDx-UM.
- The company raised approximately $330 million net through follow-on stock offerings in 2020, materially increasing cash and shares outstanding. Common shares outstanding were 24.8 million at year-end.
Outlook, risks and unusual items
Management stated that existing cash and anticipated product collections should fund operations for the foreseeable future, while cautioning that estimates depend on assumptions, including COVID-19 impacts. No specific revenue or earnings guidance was provided. The company planned to expand its commercial organization, continue evidence-generation and product development, and expected to provide more detail on pipeline products before the end of 2021. It said three to five new tests could potentially launch by the end of 2025, with an estimated $3.6 billion of additional U.S. addressable market; these are plans and estimates, not assured outcomes.
- Reimbursement and collections: Revenue depends on a concentrated group of payors; coverage and payment rates may change, and revenue recognition includes estimates for variable consideration. An appeal covering 2,698 historical DecisionDx-Melanoma claims was denied in March 2020; Castle appealed and had recognized no revenue for those claims pending the appeal.
- COVID-19 and adoption: Further disruption to patient visits, physician access, and testing demand could affect volume. The business also depends on clinicians adopting tests and payors covering them.
- Regulatory and operational exposure: Tests are marketed as laboratory-developed tests under the FDA’s enforcement-discretion policy, which could change. The company also relies on third-party sample handling and certain sole or limited suppliers, and its laboratory and tumor-sample database are important operating assets.
- Unusual items: FY2020 included $1.9 million of CARES Act provider relief income, whose recognition was reversed and later reinstated as program requirements changed. The $8.3 million Medicare advance is a liability, not revenue.
- Profitability and dilution: Castle reported a $10.3 million annual net loss and expects continued investment and higher expenses. It had $57.1 million of unrecognized stock-based compensation cost at year-end. Additional financing could dilute shareholders, although management said it did not then expect to need it for the foreseeable future.
Most important facts for investors to verify
- Whether test volumes, particularly DecisionDx-Melanoma, recover from pandemic-related disruption and whether new products gain meaningful adoption.
- Whether payor concentration, Medicare coverage and reimbursement rates support revenue growth and cash collections; track the outcome of the historical-claims appeal.
- How much of reported operating cash flow reflects sustainable collections versus the Medicare advance and other working-capital movements.
- Whether the planned launches, clinical studies and pipeline timetable progress as described, and whether resulting products obtain coverage.
- How the $8.3 million Medicare advance is recouped, and the effect of ongoing operating investment, stock compensation and potential share issuance on liquidity and per-share results.